Charles Schwab Investment Management Inc. Boosts Holdings in XOMA Co. (NASDAQ:XOMA)

Charles Schwab Investment Management Inc. grew its position in shares of XOMA Co. (NASDAQ:XOMA) by 5.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,113 shares of the biotechnology company’s stock after buying an additional 1,276 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in XOMA were worth $607,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in XOMA. BNP Paribas Financial Markets raised its holdings in XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares in the last quarter. New York State Common Retirement Fund increased its position in XOMA by 51.2% during the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 800 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of XOMA during the 4th quarter worth approximately $206,000. Rhumbline Advisers lifted its holdings in shares of XOMA by 18.1% in the 4th quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock valued at $291,000 after buying an additional 1,699 shares during the period. Finally, Barclays PLC boosted its stake in shares of XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 8,447 shares in the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on XOMA. HC Wainwright reiterated a “buy” rating and issued a $104.00 price objective on shares of XOMA in a research report on Friday. StockNews.com upgraded shares of XOMA from a “sell” rating to a “hold” rating in a report on Friday, March 21st.

Insider Buying and Selling at XOMA

In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CIO Bradley Sitko acquired 4,134 shares of the business’s stock in a transaction that occurred on Friday, March 21st. The shares were bought at an average price of $23.89 per share, with a total value of $98,761.26. Following the completion of the transaction, the executive now directly owns 10,484 shares in the company, valued at approximately $250,462.76. The trade was a 65.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 7.20% of the stock is currently owned by insiders.

XOMA Stock Performance

XOMA opened at $19.93 on Tuesday. XOMA Co. has a 1-year low of $19.79 and a 1-year high of $35.00. The stock has a market cap of $238.74 million, a P/E ratio of -5.73 and a beta of 1.00. The stock’s 50 day simple moving average is $23.63 and its 200 day simple moving average is $26.84. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52.

XOMA (NASDAQ:XOMA) last posted its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.17). The firm had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.75 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. As a group, equities analysts anticipate that XOMA Co. will post -1.41 EPS for the current fiscal year.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.